Continuous intrathecal baclofen infusion for intractable spastic cerebral palsy - Is it worth it?

Nature Clinical Practice Neurology

Volumn 4, Issue 9, 2008, Pages 476-477

  Russman, Barry S ^a  

^a OREGON HEALTH AND SCIENCE UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BACLOFEN;

CAREGIVER; CEREBRAL PALSY; CLINICAL TRIAL; CONTINUOUS INFUSION; COST EFFECTIVENESS ANALYSIS; COST UTILITY ANALYSIS; HEALTH CARE COST; HOSPITAL PATIENT; HOSPITALIZATION; HUMAN; IMPLANTATION; INFUSION PUMP; LENGTH OF STAY; MEDICAL FEE; MUSCLE TONE; NOTE; OCCUPATIONAL THERAPY; PATIENT SATISFACTION; PHYSIOTHERAPY; PRIORITY JOURNAL; QUALITY ADJUSTED LIFE YEAR; QUALITY OF LIFE; TREATMENT RESPONSE;

EID: 51849151104     PISSN: 1745834X     EISSN: 17458358     Source Type: Journal    
DOI: 10.1038/ncpneuro0868     Document Type: Note

References (5)

1. Pranzatelli MR (1996) Oral pharmacotherapy for the movement disorders of cerebral palsy. J Child Neurol 11 (Suppl 1): S13-S22
2. Nemer MR et al. (2006) Validation of a care and comfort hypertonicity questionnaire. Dev Med Child Neurol 48: 181-187
3. Gooch JL et al. (2004) Care provider assessment of intrathecal baclofen in children. Dev Med Child Neurol 46: 548-552
4. Hoving MA et al. (2008) Intrathecal baclofen therapy in children with intractable spastic cerebral palsy: A cost-effectiveness analysis. Dev Med Child Neurol 50:. 450-455
5. de Lissovoy G et al. (2007) Cost-effectiveness of intrathecal baclofen therapy for the treatment of severe spasticity associated with cerebral palsy. J Child Neurol 22: 49-59